Pelosi's Missed Micron Opportunity: An $8.6 Million Lapse in Stock Options
#Money
Nancy Pelosi's husband, Paul Pelosi, incurred a significant loss by prematurely selling Micron Technology call options in 2022, missing out on substantial potential gains. Similarly, an early sale of Nvidia stock options in 2022 also led to considerable foregone profits for the couple, highlighting a pattern of missed investment opportunities despite their generally profitable trading history.
Nebius Group N.V. (NASDAQ: NBIS) shares saw a decline on Friday, influenced by a broader slowdown in the artificial intelligence infrastructure sector. This dip is attributed to changing macroeconomic forecasts and substantial insider selling. A strong labor market report for May, which exceeded expectations, has led to a more hawkish stance from the Federal Reserve, impacting market sentiment. Additionally, a major share divestment by NVIDIA Inc. director Mark Stevens added to the downward pressure, despite Nebius retaining significant institutional support and its rapid growth being acknowledged by NVIDIA's CEO.
Ciena Corporation reported impressive fiscal second-quarter results, surpassing revenue and earnings expectations. The company also raised its full-year guidance, driven by robust demand, particularly in the Direct Cloud segment fueled by AI investments. However, despite the strong performance and positive analyst outlooks, Ciena's stock experienced a decline post-announcement, indicating investor caution amid the rising guidance.
G-III Apparel Stock Rises as Shoppers Get More Selective, Not Pulling Back
#Money
G-III Apparel Group's stock surged nearly 7% after the company reported better-than-expected first-quarter results and raised its fiscal 2027 earnings outlook. Despite geopolitical tensions and economic uncertainty, consumer demand for apparel remains resilient, with a shift towards more selective buying. The company's owned brands, like Donna Karan and DKNY, showed strong growth, particularly in digital sales. G-III's planned acquisition of Marc Jacobs is expected to further boost revenue.
Praxis Precision Medicines Reveals POWER1 Study Outcomes for Focal Onset Seizures
#Money
Praxis Precision Medicines (PRAX) has released the findings from its Phase 2/3 POWER1 study, evaluating vormatrigine for focal onset seizures. While primary efficacy goals were not fully met, the study demonstrated positive effectiveness in higher doses, alongside a favorable safety profile and low patient discontinuation rates. The company plans to leverage these insights for future drug development and remains committed to commercializing other key therapies.
